Current Report Filing (8-k)
February 19 2016 - 4:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 15, 2016
PHARMATHENE, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-32587 |
|
20-2726770 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
One Park Place, Suite 450
Annapolis, Maryland |
|
21401 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number including
area code: (410) 269-2600
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 15, 2016, in accordance with the recommendation
of the Compensation Committee of the Board of Directors of PharmAthene, Inc. (the “Company”), the Board of Directors
approved the award of a $125,000 bonus to John Gill, the Company's President and Chief Executive Officer, based upon its conclusion
that Mr. Gill had satisfied 100% of his performance objectives for a 2015 bonus.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PHARMATHENE, INC. |
|
|
|
By: |
/s/ Philip MacNeill |
|
|
Name: |
Philip MacNeill |
|
|
Title: |
Vice President, Chief Financial Officer, Treasurer and Secretary |
Dated: February 19, 2016
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pharmathene, (delisted) (AMEX:PIP)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Pharmathene, (delisted) (American Stock Exchange): 0 recent articles
More Pharmathene, Inc News Articles